NRx CEO Javitt retires; Robert Besthof named interim CEO; narrows focus to US

NRX Pharmaceuticals, Inc.

Dr. Jonathan Javitt retired as CEO effective March 8, 2022; becomes Chief Scientist and remains on Board.
Robert Besthof, Head of Operations, appointed Interim CEO; received 100,000 stock options at $2.61/share.
Javitt consulting agreement: $250,000 upfront plus $75,000/month for one year.
Company narrows geographic focus to US; ceasing efforts in Georgia and Caucasus due to geopolitical environment.
Continues development of ZYESAMI for Critical COVID-19 and psychiatric pipeline including NRX-101.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jonathan Javitt

Chief Scientist

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-03-08
Successor: Robert Besthof
Filed: March 9, 2022, 6:59 PM ET

On March 8, 2022, Dr. Jonathan Javitt, MD, MPH, announced his retirement from his position as Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.

Appointed (interim)

Robert Besthof

Interim Chief Executive Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-03-08
Filed: March 9, 2022, 6:59 PM ET

On March 8, 2022, the Board appointed Mr. Robert Besthof to serve as Interim Chief Executive Officer of the Company during the transition.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Javitt retired as Chief Scientist at NRX Pharmaceuticals, Inc..

Action: retired
Role: Chief Scientist

Exact text from the filing

On March 8, 2022, Dr. Jonathan Javitt, MD, MPH, announced his retirement from his position as Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Besthof was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On March 8, 2022, the Board appointed Mr. Robert Besthof to serve as Interim Chief Executive Officer of the Company during the transition.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-000983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.